Discovering the value of comprehensive syndromic panels

Discovering the value of comprehensive syndromic panels

Syndromic panels may offer a better prognosis for patients, increased hospital cost savings, and help address the AMR crisis.

Read on healthcaretransformers.com

Medigy Insights

Bloodstream infections pose a grave threat, often leading to sepsis, a condition responsible for at least 11 million deaths globally each year and presenting a significant burden to the healthcare industry. As the costs associated with sepsis care are exorbitant, healthcare leaders have a compelling opportunity to employ multiplexed syndromic panels. These panels offer clinicians timely and accurate results, potentially improving patient prognosis, reducing hospital expenses, and aiding in combating the antimicrobial resistance crisis.

Bloodstream infections, whether bacterial or fungal, can swiftly escalate to sepsis, the leading cause of hospital fatalities, readmissions, and expenses worldwide. With an estimated 47 to 50 million annual sepsis cases contributing to the staggering death toll, there exists a pressing need for enhanced diagnostic strategies to guide targeted treatments.

Early detection of sepsis-causing infections significantly impacts patient outcomes. Alarmingly, studies indicate that each hour of delayed appropriate antimicrobial treatment increases the risk of sepsis mortality by 8%. However, the traditional method of pathogen identification through blood cultures followed by subculture, although cost-effective, often lacks sensitivity and specificity for certain pathogens, requiring multiple days for identification. This delay can lead to adverse outcomes, including patient fatalities.

Given the alarming statistic of one sepsis-related death every 2.8 seconds, healthcare leaders must consider adopting comprehensive molecular approaches that incorporate syndromic blood culture identification panels. These panels can enable early diagnosis, potentially saving lives and reducing healthcare system expenditures.

Sepsis Impact and Syndromic Panels' Value: Sepsis can affect anyone, resulting in death following an infectious disease, as the immune system inadvertently damages the body's organs and tissues. Certain groups, such as premature infants, neonates, adults over 60, immunocompromised individuals, and those with chronic illnesses, face a higher risk of developing sepsis. Survivors of sepsis may experience long-term complications known as post-sepsis syndrome (PSS), which can manifest as chronic depression, muscle weakness, joint pain, confusion, and anxiety.

The economic toll of sepsis is substantial, with hospital-acquired bloodstream infections costing an average of US$ 43,000 for a 10-day hospital stay. For candidiasis, caused by yeast, costs can exceed US$ 150,000, with mortality rates ranging from 50-70%. This places a staggering US$ 38 billion burden on US healthcare systems annually, underscoring the critical importance of identifying the root cause of infections promptly.

Traditional microbiological methods reliant on blood cultures for diagnosing bloodstream infections are time-consuming, necessitating rapid adoption of molecular syndromic panels. These panels offer clinicians expedited and precise results, potentially saving lives and reducing healthcare expenditures.

The Benefits of Syndromic Panels: Syndromic blood culture identification panels swiftly and comprehensively diagnose causative organisms and resistance profiles, enabling informed treatment decisions. These rapid multiplex nucleic acid amplification tests outperform conventional methods, offering faster results with reduced turnaround and hands-on time.

Key characteristics of high-quality syndromic panels include broad pathogen coverage, rapid results delivery, minimal personnel involvement, and the ability to detect resistance genes. Rapid differentiation between contaminants and infections is crucial, as contaminants account for up to 15-30% of organisms isolated in certain hospital settings. Syndromic panels equipped with these features ensure accurate identification, cost reduction, and optimal patient management.

Addressing Antimicrobial Resistance: Bacterial antimicrobial resistance claims 1.27 million lives annually and has contributed to 4.95 million deaths globally in 2019 alone. Misuse and overuse of antimicrobials drive this crisis, emphasizing the need for accurate detection techniques to guide targeted treatments and mitigate further resistance development.

Syndromic panels detecting antimicrobial resistance genes offer invaluable insights for infection control, expedited therapy, and optimal patient care. Beyond providing rapid and accurate results, these panels play a pivotal role in combating the global antimicrobial resistance crisis.

Enabling Patient-Centered Care: To enhance clinical outcomes for septic patients, healthcare leaders must harness syndromic panels for rapid and reliable diagnosis of bloodstream infections. Multiplex tests offer swift results and minimal hands-on time, empowering physicians to prescribe optimal therapeutics and reduce hospital stays. Pinpointing the exact cause of bloodstream infections facilitates better prognosis, heightened hospital cost savings, and effective management of the antimicrobial resistance crisis.




Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on May 28, 2024 at 11:33am